AstraZeneca Prevails In Trial Over Diabetes Drug Patent
A Delaware federal judge ruled Thursday that AstraZeneca's patents covering its $3.5 billion diabetes drugs Onglyza and Kombiglyze XR were not invalid for being obvious, though he denied the pharmaceutical company's...To view the full article, register now.
Already a subscriber? Click here to view full article